当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Pramita Waghambare, Prabha Singh, Pramila Chaubey*
Colorectal cancer (CRC) is considered as the third most common cancer and the fourth foremost cause of death worldwide. Various
attempts have been made to diagnose and treat CRC. However, the incidence and mortality rates are still high. For CRC, currently available
chemotherapy delivers the drugs usually to both cancerous as well as normal cells, hence resulting in various undesirable side effects.
Therefore, nowadays more emphasis is been given on targeted drug delivery systems as it directly reaches to site of action with minimal
unwanted side effects. This review focuses on novel approaches for the treatment of CRC. Plant-derived drugs shows promising anticancer
activity and have various advantages over chemotherapeutics agents have also been explored. The current paper also elaborates on
synthetic drugs, plant-derived drugs and drugs targeting to overexpressed proteins in CRC including recent clinical trials in combinations
with other chemotherapeutics for the treatment of CRC.